銀屑病

疾病簡(jiǎn)介
銀屑病是一種慢性的、非傳染性的、疼痛的、毀容的、致殘的疾病,無(wú)治愈方法,對(duì)患者的生存質(zhì)量(QoL)有著極大的負(fù)面影響。任何年齡都有發(fā)病可能,最常見(jiàn)于50 至69 歲之間1。各國(guó)公布的銀屑病患病率在0.09%2至11.43%3之間,因此銀屑病是一個(gè)嚴(yán)重的全球性難題。
發(fā)病原因

銀屑病病因尚不明確,證據(jù)顯示有遺傳傾向4。免疫系統(tǒng)在銀屑病發(fā)病時(shí)扮演了何種角色也是研究的熱點(diǎn)。盡管有人提出銀屑病可能是一種自體免疫性疾病,然而至今沒(méi)有明確導(dǎo)致這種疾病的自身抗原。外源和內(nèi)源誘因也可引起銀屑病,包括輕微創(chuàng)傷、曬傷、感染、系統(tǒng)用藥以及壓力5。

臨床表現(xiàn)

銀屑病發(fā)于皮膚和指甲,并伴隨一系列合并癥。皮膚損傷位于局部或全身,對(duì)稱(chēng)居多,邊界清晰,紅疹和斑塊,通常覆蓋白色或銀色的鱗片。皮損引起瘙癢和刺痛。1.3%6至34.7%7的銀屑病患者患有慢性炎性關(guān)節(jié)炎(銀屑病性關(guān)節(jié)炎),導(dǎo)致關(guān)節(jié)變形和殘疾。4.2%至69%的銀屑病病人有指甲病變8,9,10。報(bào)告稱(chēng)銀屑病患者更易患心血管疾病和其他非傳染性疾?。∟CDs)5,11,12

疾病治療

銀屑病的治療仍基于控制癥狀??捎镁植亢腿碇委熞约肮饩€療法。臨床常結(jié)合使用以上治療方法?;颊咄ǔP杞K身治療緩解疾病。至今為止,還未有完全治愈銀屑病的方法。此外,銀屑病患者的護(hù)理不僅包括治療皮損及關(guān)節(jié)損傷,還包括辨別和處理已經(jīng)出現(xiàn)或可能出現(xiàn)的常見(jiàn)合并癥,例如心血管和代謝疾病以及心理疾病。
  


1.  Institute for Health Metrics and Evaluation (IHME). Global Burden of Disease Study 2010: Results by Cause 1990–2010. Seattle: IHME; 2012.
2.  Gibbs S. Skin disease and socioeconomic conditions in rural Africa: Tanzania. Int J Dermatol. 1996;35(9):633–9.
3.  Danielsen K, Olsen AO, Wilsgaard T, Furberg AS. Is the prevalence of psoriasis increasing? A 30–year follow-up of a population–based cohort. Br J Dermatol. 2013;168:1303–10.
4.  Harden JL, Krueger JG, Bowcock AM. The immunogenetics of psoriasis: a comprehensive review. J Autoimmun. 2015;64:66–73.
5.  Boehncke W-H, Schon MP. Psoriasis. Lancet. 2015;386(9997):983–94.
6.  Bedi TR. Clinical profile of psoriasis in North India. Indian J Dermatol Venereol Leprol. 1995;61(4):202–5.
7.  Pariser D, Schenkel B, Carter C, Farahi K, Brown TM, Ellis CN, and Psoriasis Patient Interview Study Group. A multicenter, non-interventional study to evaluate patient-reported experiences of living with psoriasis. J Dermatol Treat. 2015;1–8.
8.  Alshami MA. Clinical profile of psoriasis in Yemen, a 4-year retrospective study of 241 patients. J Eur Acad Dermatol Venereol. 2010;24(Suppl. 4):14.
9.  Falodun OA. Characteristics of patients with psoriasis seen at the dermatology clinic of a tertiary hospital in Nigeria: a 4-year review 2008–2012. J Eur Acad Dermatol Venereol. 2013;27(Suppl. 4).
10.  Reich K, Kruger K, Mossner R, Augustin M. Epidemiology and clinical pattern of psoriatic arthritis in Germany: a prospective interdisciplinary epidemiological study of 1511 patients with plaque-type psoriasis. Br J Dermatol. 2009;160(5):1040–7.
11.  Augustin M, Radtke MA, Glaeske G, Reich K, Christophers E, Schaefer I et al. Epidemiology and Comorbidity in Children with Psoriasis and Atopic Eczema. Dermatology. 2015;231(1):35–40.
12.  Vena GA, Altomare G, Ayala F, Berardesca E, Calzavara-Pinton P, Chimenti S et al. Incidence of psoriasis and association with comorbidities in Italy: a 5-year observational study from a national primary care database. Eur J Dermatol. 2010;20(5):593–8.

CP-84792 Approved date 2019-3-29